GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (FRA:0N6A) » Definitions » Cyclically Adjusted PS Ratio

TME Pharma NV (FRA:0N6A) Cyclically Adjusted PS Ratio : (As of Jun. 03, 2025)


View and export this data going back to 2018. Start your Free Trial

What is TME Pharma NV Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


TME Pharma NV Cyclically Adjusted PS Ratio Historical Data

The historical data trend for TME Pharma NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Cyclically Adjusted PS Ratio Chart

TME Pharma NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TME Pharma NV Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TME Pharma NV's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, TME Pharma NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TME Pharma NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's Cyclically Adjusted PS Ratio falls into.


;
;

TME Pharma NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

TME Pharma NV's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec24 is calculated as:

For example, TME Pharma NV's adjusted Revenue per Share data for the fiscal year that ended in Dec24 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec24 (Change)*Current CPI (Dec24)
=0/127.0412*127.0412
=0.000

Current CPI (Dec24) = 127.0412.

TME Pharma NV Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201512 1.433 99.717 1.826
201612 3.458 101.217 4.340
201712 0.000 102.617 0.000
201812 0.000 104.217 0.000
201912 0.000 105.818 0.000
202012 0.000 105.518 0.000
202112 0.000 110.384 0.000
202212 0.000 119.345 0.000
202312 0.000 123.773 0.000
202412 0.000 127.041 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TME Pharma NV  (FRA:0N6A) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


TME Pharma NV Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TME Pharma NV Business Description

Industry
Traded in Other Exchanges
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

TME Pharma NV Headlines

No Headlines